Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 10, 13, 1, 22, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) - Overview
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
Algernon Pharmaceuticals Inc
Algomedix Inc
Allena Pharmaceuticals Inc
Angion Biomedica Corp
apceth Biopharma GmbH
Arch Biopartners Inc
Aronora Inc
AstraZeneca Plc
Bayer AG
BioAegis Therapeutics Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
Cellmid Ltd
Cinkate Corp
Corvidia Therapeutics Inc
DiaMedica Therapeutics Inc
Dimerix Ltd
Dizal (Jiangsu) Pharmaceutical Co Ltd
DJS Antibodies Ltd
DURECT Corp
Ember Therapeutics Inc (Inactive)
Evotec SE
G3 Pharmaceuticals Inc
GNI Group Ltd
Indalo Therapeutics Inc
Kaleido Biosciences Inc
KBP BioSciences Co Ltd
KidneyCure Ltd
Kintai Therapeutics Inc
Klotho Therapeutics Inc
Liminal BioSciences Inc
Merck & Co Inc
Novartis AG
OPKO Health Inc
Opsidio LLC
OrthoTrophix Inc
ProKidney LLC
Reata Pharmaceuticals Inc
Redx Pharma Plc
Renibus Therapeutics Inc
Resverlogix Corp
Sarfez Pharmaceuticals Inc
Scohia Pharma Inc
Sentien Biotechnologies Inc
Sphaera Pharma Pte Ltd
Theravance Biopharma Inc
Unicocell Biomed Co Ltd
Unity Biotechnology Inc
Vascular BioSciences
VESSL Therapeutics Ltd
Vidasym Inc
Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
Appendix